- Home
- SKX vs RPRX Comparison
SKX vs RPRX Comparison
Compare SKX & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKX
- RPRX
- Stock Information
- Founded
- SKX 1992
- RPRX 1996
- Country
- SKX United States
- RPRX United States
- Employees
- SKX N/A
- RPRX N/A
- Industry
- SKX Shoe Manufacturing
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- SKX Consumer Discretionary
- RPRX Health Care
- Exchange
- SKX Nasdaq
- RPRX Nasdaq
- Market Cap
- SKX 10.4B
- RPRX 11.7B
- IPO Year
- SKX 1999
- RPRX 2020
- Fundamental
- Price
- SKX $73.80
- RPRX $30.30
- Analyst Decision
- SKX Buy
- RPRX Strong Buy
- Analyst Count
- SKX 12
- RPRX 6
- Target Price
- SKX $78.00
- RPRX $41.67
- AVG Volume (30 Days)
- SKX 1.7M
- RPRX 3.8M
- Earning Date
- SKX 02-06-2025
- RPRX 02-13-2025
- Dividend Yield
- SKX N/A
- RPRX 2.76%
- EPS Growth
- SKX 18.90
- RPRX 518.56
- EPS
- SKX 4.05
- RPRX 2.55
- Revenue
- SKX $8,717,875,000.00
- RPRX $2,266,003,000.00
- Revenue This Year
- SKX $13.31
- RPRX $14.54
- Revenue Next Year
- SKX $10.23
- RPRX $10.94
- P/E Ratio
- SKX $18.10
- RPRX $11.88
- Revenue Growth
- SKX 10.10
- RPRX N/A
- 52 Week Low
- SKX $55.67
- RPRX $24.05
- 52 Week High
- SKX $75.09
- RPRX $31.66
- Technical
- Relative Strength Index (RSI)
- SKX 69.09
- RPRX 75.65
- Support Level
- SKX $68.68
- RPRX $29.67
- Resistance Level
- SKX $73.20
- RPRX $31.09
- Average True Range (ATR)
- SKX 1.99
- RPRX 0.70
- MACD
- SKX 0.20
- RPRX 0.51
- Stochastic Oscillator
- SKX 99.87
- RPRX 86.63
About SKX Skechers U.S.A. Inc.
Skechers USA Inc is a lifestyle footwear company under the Skechers GO brand name. Products offered include various styles of women's shoes, men's shoes, girl's shoes, boy's shoes, performance shoes, and work shoes. Allied products offered are apparel, bags, eyewear, toys, and more. Its products are available for sale at department and specialty stores, athletic and independent retailers, boutiques, and internet retailers. The company's operating segments includes Wholesale and Direct-to-Consumer. It generates maximum revenue from the Wholesale segment.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.